Original articleRelapse Rate of Uveitis Post-Methotrexate Treatment in Juvenile Idiopathic Arthritis
Section snippets
Patients and Methods
Medical data of MTX-treated patients with JIA-associated uveitis attending a tertiary center for (pediatric) uveitis between 1989 and 2009 were studied retrospectively. JIA was diagnosed and classified by a pediatric rheumatologist in agreement with the International League of Associations for Rheumatology criteria.16 Diagnosis of uveitis was made by an ophthalmologist specialized in pediatric uveitis. The diagnostic criteria for uveitis were those defined by the International Uveitis Study
Results
Twenty-two patients with active uveitis at initiation of MTX were included in the study. General baseline characteristics of the study population are listed in Table 1.
Discussion
Our study demonstrates that the majority (69%) of patients with inactive uveitis at the moment of withdrawal of MTX develop a relapse at a later stage. Most of them had a relapse of uveitis within the first year after discontinuation of MTX therapy. The data also indicate that a longer period of inactivity of uveitis before withdrawal, together with older age and/or longer treatment with MTX, might protect against relapses of uveitis. Furthermore, our study confirms the earlier results about
References (19)
- et al.
Analysis of pediatric uveitis cases at a tertiary referral center
Ophthalmology
(2005) - et al.
Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study
Ophthalmology
(2001) - et al.
Course, complications, and outcome of juvenile arthritis-related uveitis
J AAPOS
(2008) - et al.
Treatment of uveitis with methotrexate
Am J Ophthalmol
(1969) - et al.
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients
Ophthalmology
(2001) - et al.
Low-dose methotrexate therapy for ocular inflammatory disease
Ophthalmology
(1992) - et al.
Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis
J Pediatr
(1998) - et al.
International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease
Am J Ophthalmol
(1987) - et al.
Visual loss in uveitis of childhood
Br J Ophthalmol
(2003)
Cited by (89)
Taiwan ocular inflammation society consensus recommendations for the management of juvenile idiopathic arthritis-associated uveitis
2024, Journal of the Formosan Medical AssociationUveitis in Children and Adolescents
2021, Rheumatic Disease Clinics of North AmericaCitation Excerpt :Some studies suggest that patients who initiated systemic immunomodulatory therapy within the first year of uveitis diagnosis and achieved remission within 6 months had a higher success of remaining in remission off of medications.143,144 Longer duration of therapy may be important, because patients in remission on MTX for at least 2 years had improved success in weaning off medication than those in remission for a shorter duration.147,148 Thus, guidelines recommend at least 2 years of remission on immunomodulatory therapy before attempting to wean medications.38,102
Factors Predictive of Remission of Chronic Anterior Uveitis
2020, OphthalmologyDiagnostic and therapeutic considerations in pediatric uveitis
2024, Spektrum der AugenheilkundeChinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody
2024, Chinese Journal of Ocular Fundus DiseasesDiagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
2024, Pediatric Drugs